AP1886A - Energy efficient window - Google Patents
Energy efficient windowInfo
- Publication number
- AP1886A AP1886A AP2005003310A AP2005003310A AP1886A AP 1886 A AP1886 A AP 1886A AP 2005003310 A AP2005003310 A AP 2005003310A AP 2005003310 A AP2005003310 A AP 2005003310A AP 1886 A AP1886 A AP 1886A
- Authority
- AP
- ARIPO
- Prior art keywords
- energy efficient
- efficient window
- window
- energy
- efficient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AP2005003310A AP1886A (en) | 2001-02-16 | 2002-11-13 | Energy efficient window |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26927601P | 2001-02-16 | 2001-02-16 | |
PCT/CA2002/000175 WO2002066511A2 (en) | 2001-02-16 | 2002-02-15 | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
AP2005003310A AP1886A (en) | 2001-02-16 | 2002-11-13 | Energy efficient window |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2005003310A0 AP2005003310A0 (en) | 2005-06-30 |
AP1886A true AP1886A (en) | 2008-09-20 |
Family
ID=23026568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2005003310A AP1886A (en) | 2001-02-16 | 2002-11-13 | Energy efficient window |
Country Status (14)
Country | Link |
---|---|
US (3) | US7112567B2 (pt) |
EP (2) | EP1360202B1 (pt) |
JP (4) | JP4280070B2 (pt) |
AP (1) | AP1886A (pt) |
AT (1) | ATE396202T1 (pt) |
AU (1) | AU2002233089B2 (pt) |
CA (1) | CA2436399A1 (pt) |
CY (1) | CY1108274T1 (pt) |
DE (1) | DE60226702D1 (pt) |
DK (1) | DK1360202T3 (pt) |
EA (1) | EA006160B1 (pt) |
ES (1) | ES2307718T3 (pt) |
PT (1) | PT1360202E (pt) |
WO (1) | WO2002066511A2 (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
CA2501421A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US7112567B2 (en) | 2001-02-16 | 2006-09-26 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
DK1412384T3 (da) * | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
JP4936884B2 (ja) * | 2003-06-03 | 2012-05-23 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
EP1633391B1 (en) * | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
CN102784386A (zh) * | 2003-11-20 | 2012-11-21 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
PL2100904T3 (pl) * | 2004-04-23 | 2011-05-31 | Conjuchem Biotechnologies Inc | Stała faza do zastosowania w sposobie oczyszczania koniugatów albuminy |
PL1789434T3 (pl) * | 2004-08-31 | 2014-07-31 | Novo Nordisk As | Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek |
JP5197012B2 (ja) | 2004-11-01 | 2013-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | 大腸連続性を伴う短腸症候群患者の治療 |
AU2005303777B2 (en) | 2004-11-12 | 2010-12-16 | Novo Nordisk A/S | Stable formulations of insulinotropic peptides |
EP2295452A1 (en) | 2005-05-04 | 2011-03-16 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
US20070212355A1 (en) * | 2005-10-24 | 2007-09-13 | Baker Audrey E | GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US7812121B2 (en) * | 2006-08-31 | 2010-10-12 | Baker Audrey E | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
CA2669806C (en) * | 2006-11-08 | 2018-10-02 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
US20090099074A1 (en) * | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
CA2699008A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2231191A2 (en) * | 2007-12-11 | 2010-09-29 | ConjuChem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
EP4074327A1 (en) * | 2008-06-27 | 2022-10-19 | Duke University | Therapeutic agents comprising elastin-like peptides |
EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
CN103314010B (zh) * | 2010-08-30 | 2015-03-04 | Nps制药股份有限公司 | h[Gly2]GLP-2的固相合成 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
CA2872315A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
NZ701573A (en) | 2012-05-17 | 2017-04-28 | Extend Biosciences Inc | Carriers for improved drug delivery |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
AU2016343775B2 (en) * | 2015-10-28 | 2021-07-29 | Tufts Medical Center | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
CN118085104A (zh) | 2016-07-11 | 2024-05-28 | Opko生物科学有限公司 | 长效凝血因子及其制备方法 |
BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
MX2020004453A (es) * | 2017-09-28 | 2020-07-24 | Hanmi Pharm Ind Co Ltd | Conjugados de accion prolongada de derivados de glp-2. |
CN108395469A (zh) * | 2018-02-01 | 2018-08-14 | 滨海吉尔多肽有限公司 | 一种假脯氨酸二肽的合成方法 |
WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
EP3628682A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
CA3129576A1 (en) | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ,インク. | Gpr119アゴニスト |
US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope Inc | AMPK ACTIVATORS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1160380A (en) * | 1966-12-22 | 1969-08-06 | Ford Motor Co | Vehicle Engine Arrangement. |
EP0086345A1 (de) * | 1982-01-19 | 1983-08-24 | Josef Gartner & Co. | Isolierverglasung |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
US4462941A (en) * | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
DK608589D0 (da) | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
US5843440A (en) * | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
US5612034A (en) | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
WO1992017492A1 (en) | 1991-04-05 | 1992-10-15 | Genentech, Inc. | PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a? |
DE4122210C2 (de) | 1991-07-04 | 1999-04-01 | Deutsches Krebsforsch | Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung |
JPH08501075A (ja) | 1992-06-12 | 1996-02-06 | ディー イー エス − ティー ワイ アール ダイノルフィン パートナーシップ | des−Tyrダイノルフィン類似体 |
EP0602290B1 (en) | 1992-12-04 | 1999-08-25 | ConjuChem, Inc. | Antibody-conjugated Hepatitis B surface antigen and use thereof |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5496007A (en) * | 1994-05-13 | 1996-03-05 | Reece; Cecil L. | Device for holding out-sized documents |
JPH10511077A (ja) | 1994-08-26 | 1998-10-27 | ナンシー、 エム. リー、 | N末端基で切断されたダイノルフィン類似体を用いた鎮痛方法 |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
EP0814850A1 (en) | 1996-01-12 | 1998-01-07 | Redcell Canada Inc. | Cellular and serum protein anchors for diagnostic imaging |
US6277583B1 (en) | 1996-02-07 | 2001-08-21 | Conjuchem, Inc. | Affinity labeling libraries and applications thereof |
EP0915910B1 (de) | 1996-06-05 | 2006-01-18 | Roche Diagnostics GmbH | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US5840733A (en) | 1996-07-01 | 1998-11-24 | Redcell, Canada, Inc. | Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes |
US5994500A (en) * | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
JP2000517308A (ja) | 1996-08-30 | 2000-12-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―2誘導体 |
AU4351897A (en) | 1996-09-16 | 1998-04-02 | Conjuchem, Inc. | Affinity labeling libraries with tagged leaving groups |
DK1012186T3 (da) * | 1996-12-06 | 2002-11-04 | Amgen Inc | Keratinocyt-vækstfaktorer og anvendelser deraf |
US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
US6723530B1 (en) | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
US6051557A (en) * | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
AU749914B2 (en) | 1997-08-08 | 2002-07-04 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
ATE216402T1 (de) | 1997-11-07 | 2002-05-15 | Conjuchem Inc | Opioid-konjugate mit endogenen trägerproteinen |
AU1519699A (en) | 1997-11-07 | 1999-05-31 | Conjuchem, Inc. | Affinity markers for human serum albumin |
US6437092B1 (en) | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
WO1999024071A1 (en) | 1997-11-12 | 1999-05-20 | Alza Corporation | Method for decreasing self-association of polypeptides |
DE69838916T2 (de) | 1997-11-14 | 2008-12-18 | Amylin Pharmaceuticals, Inc., San Diego | Neuartige exendin agonisten |
JP2001523688A (ja) | 1997-11-14 | 2001-11-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 新規エキセンジン・アゴニスト化合物 |
AU2712899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
US6107489A (en) | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
US20030170250A1 (en) | 1998-03-23 | 2003-09-11 | Ezrin Alan M. | Local delivery of long lasting therapeutic agents |
AU748496B2 (en) | 1998-03-23 | 2002-06-06 | Conjuchem, Inc. | Local delivery of long lasting therapeutic agents |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US20040266673A1 (en) | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
DK1105409T3 (da) | 1999-05-17 | 2006-07-03 | Conjuchem Inc | Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter |
CA2373252C (en) | 1999-05-17 | 2007-08-07 | Conjuchem Inc. | Long lasting anti-angiogenic peptides |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
CN1351611A (zh) | 1999-05-17 | 2002-05-29 | 康久化学公司 | 病毒感染的长效融合肽抑制剂 |
CA2501421A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Long lasting exendin-4 |
US7144854B1 (en) | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE19926475A1 (de) | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
CA2383794A1 (en) | 1999-09-07 | 2001-03-15 | Conjuchem Inc. | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
US7090851B1 (en) | 1999-09-10 | 2006-08-15 | Conjuchem Inc. | Long lasting fusion peptide inhibitors of viral infection |
DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
EP1355941A2 (en) | 2001-02-02 | 2003-10-29 | ConjuChem, Inc. | Long lasting growth hormone releasing factor derivatives |
US7112567B2 (en) | 2001-02-16 | 2006-09-26 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
DE60229677D1 (de) | 2001-05-31 | 2008-12-11 | Conjuchem Biotechnologies Inc | Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion |
US6882816B2 (en) * | 2002-02-19 | 2005-04-19 | Matsushita Electric Industrial Co., Ltd. | Developing device with developer circulating path |
JP2006514607A (ja) | 2002-07-31 | 2006-05-11 | コンジュケム,インコーポレーテッド | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
WO2005012346A1 (en) | 2003-07-25 | 2005-02-10 | Conjuchem, Inc. | Long lasting insulin derivatives and methods thereof |
PL2100904T3 (pl) | 2004-04-23 | 2011-05-31 | Conjuchem Biotechnologies Inc | Stała faza do zastosowania w sposobie oczyszczania koniugatów albuminy |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
JP2009520469A (ja) | 2005-12-22 | 2009-05-28 | コンジュクヘム ビオテクフノロギエス インコーポレイテッド | アルブミンと治療薬との前もって形成された抱合体の産生のための方法 |
-
2002
- 2002-02-15 US US10/203,808 patent/US7112567B2/en not_active Expired - Fee Related
- 2002-02-15 ES ES02700079T patent/ES2307718T3/es not_active Expired - Lifetime
- 2002-02-15 EP EP02700079A patent/EP1360202B1/en not_active Expired - Lifetime
- 2002-02-15 JP JP2002566224A patent/JP4280070B2/ja not_active Expired - Lifetime
- 2002-02-15 PT PT02700079T patent/PT1360202E/pt unknown
- 2002-02-15 DE DE60226702T patent/DE60226702D1/de not_active Expired - Lifetime
- 2002-02-15 AU AU2002233089A patent/AU2002233089B2/en not_active Ceased
- 2002-02-15 EP EP08156596A patent/EP1980572A1/en not_active Withdrawn
- 2002-02-15 DK DK02700079T patent/DK1360202T3/da active
- 2002-02-15 AT AT02700079T patent/ATE396202T1/de active
- 2002-02-15 WO PCT/CA2002/000175 patent/WO2002066511A2/en active IP Right Grant
- 2002-02-15 EA EA200300857A patent/EA006160B1/ru not_active IP Right Cessation
- 2002-02-15 CA CA002436399A patent/CA2436399A1/en not_active Abandoned
- 2002-11-13 AP AP2005003310A patent/AP1886A/xx active
-
2005
- 2005-12-23 US US11/318,323 patent/US7737251B2/en not_active Expired - Fee Related
-
2008
- 2008-03-28 JP JP2008088237A patent/JP2008179652A/ja active Pending
- 2008-08-20 CY CY20081100886T patent/CY1108274T1/el unknown
- 2008-10-10 JP JP2008264644A patent/JP2009035568A/ja not_active Withdrawn
-
2009
- 2009-07-19 US US12/505,506 patent/US20090312259A1/en not_active Abandoned
-
2010
- 2010-03-03 JP JP2010046750A patent/JP2010150276A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1160380A (en) * | 1966-12-22 | 1969-08-06 | Ford Motor Co | Vehicle Engine Arrangement. |
EP0086345A1 (de) * | 1982-01-19 | 1983-08-24 | Josef Gartner & Co. | Isolierverglasung |
Also Published As
Publication number | Publication date |
---|---|
US20060217304A1 (en) | 2006-09-28 |
EA200300857A1 (ru) | 2003-12-25 |
US7112567B2 (en) | 2006-09-26 |
DK1360202T3 (da) | 2008-09-22 |
ATE396202T1 (de) | 2008-06-15 |
US7737251B2 (en) | 2010-06-15 |
WO2002066511A2 (en) | 2002-08-29 |
EP1360202B1 (en) | 2008-05-21 |
JP4280070B2 (ja) | 2009-06-17 |
JP2008179652A (ja) | 2008-08-07 |
JP2010150276A (ja) | 2010-07-08 |
US20090312259A1 (en) | 2009-12-17 |
JP2004532819A (ja) | 2004-10-28 |
CA2436399A1 (en) | 2002-08-29 |
CY1108274T1 (el) | 2014-02-12 |
EP1360202A2 (en) | 2003-11-12 |
PT1360202E (pt) | 2008-09-01 |
DE60226702D1 (de) | 2008-07-03 |
JP2009035568A (ja) | 2009-02-19 |
AP2005003310A0 (en) | 2005-06-30 |
EP1980572A1 (en) | 2008-10-15 |
AU2002233089B2 (en) | 2005-12-22 |
ES2307718T3 (es) | 2008-12-01 |
US20040248782A1 (en) | 2004-12-09 |
EA006160B1 (ru) | 2005-10-27 |
WO2002066511A3 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1886A (en) | Energy efficient window | |
EP1345516A4 (en) | ELECTRIC CURTAIN ASSEMBLY | |
GB0128954D0 (en) | Energy absorption unit | |
GB0117104D0 (en) | Window units | |
GB0113687D0 (en) | Panels | |
GB2361263B (en) | Window assembly | |
GB2378974B (en) | Window | |
GB0128209D0 (en) | Window assembly | |
GB2381820B (en) | Window assembly | |
CA91583S (en) | Window | |
CA91582S (en) | Window | |
GB0101653D0 (en) | Photovoltaic blinds | |
TW459900U (en) | Improved door structure | |
GB0115890D0 (en) | Reactor-vision windows/windsceens | |
TW502772U (en) | Improved window structure | |
CA93325S (en) | Door | |
GB2373283B (en) | Window assembly | |
GB2382359B (en) | Structural elongate elements | |
GB0006767D0 (en) | Window | |
GB2385411B (en) | Panels | |
TW486028U (en) | Improved doorframe structure | |
AU146539S (en) | A window stay | |
AU146540S (en) | A window stay | |
AU146586S (en) | A window stay | |
GB0128294D0 (en) | Combination doorframe |